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Ausblick
Przisynaptische Autoinhibition und Kotrans-
mission sind Funktionsprinzipien des Sympa-
thikus. Wie hiitte sich Hans Castorps Herz erst
gebrirdet, wzire die Freisetzung von Noradre-
nalin nicht durch ct2- (und vielleicht Pz-) Au-
toinhibition gebremst worden (Abb.1)? Si-
cher trug zur Entglutung seines Gesichts ne-
ben adrenerger auch purinerge Vasokonstrik-
tion bei (Abb. 2). Eine lebendige Wissenschaft
beantwortet Fragen und stellt Fragen: Welche
Rolle Autoinhibition und Kotransmission bei
der Informationsiibertragung vom Sympathi-
kus auf die Mm. arrectores pilorum spielen, so
daB ihn Schauer iiberliefen, das liegt im dun-
keln.
Im Winter vor jenem Faschingsdienstag
liest Hans Castorp im Liegestuhl auf seinem
Balkon Werke der Alatomie, Physiologie und
Lebenskunde (und nur noch selten ,,Ocean
steamships"). Er sinnt:
.-Was war das Leben? Man wuBte es
nicht. Es war sich seiner bewuBt, unzweifel-
haft, sobald es Leben war, aber es wuBte nicht,
was es sei. ... Niemand verstand den Stoff-
wechsel, niemand das Wesen der Nervenfunk-
tion. ... was hatte es auf sich mit der weiBen
und grauen Substanz des Kopfmarks, was mit
dem Sehhiigel, der mit dem Optikus kommu-
niziette, und mit den grauen Einlagerungen
der ,Briicke'? Die Hirn- und Riickenmarksub-
stanz war dermaBen zersetzlich, daB keine
Hoffnung bestand, je ihren Aufbau zu ergriin-
den. Was enthob beim Einschlafen die GroB-
hirnrinde ihrer Tiitigkeit? ... Aber was bedeu-
tete all dieses Unwissen im Vergleich mit der
Ratlosigkeit, in der man vor Erscheinungen
wie der des Gediichtnisses ... stand?"
Wenn,,Wesen" Metaphysisches meint,
kann Naturwissenschaft in der Tat das .,Wesen
der Nervenfunktion" nicht verstehen. Aber
manches interessante Detail kann sie enthiil-
len. 1924 war die chemische Natur der nerva-
len Informationsiibertragung schon seit drei
Jahren entdeckt, und zwar an den parasympa-
thischen Nerven zum Herzen Nach langem
Streit wurde sie auch fiir Gehirn und Riicken-
mark anerkannt. Autoinhibition und Kotrans-
mission sind demgegeniiber Prinzipien niedri-
geren Ranges. Doch haben auch sie unser Bild
der nervalen Informationsiibertragung im
Sympathikus, im iibrigen peripheren Nerven-
system und im Zentralnervensystem merklich
verzindert (eine allgemeine Ubersicht bei Star-
ke 1996).
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Prof. Hemker, given thePrize in 1985, is
a specialist in haemostasis and thrombo-
sis with a great international reputation.
He was able to develop efficient methods
to quantify and describe the factors in
blood plasma which condition haemo-
static processes. To Prof. Hemker we owe
a new understanding of the function of vi-
tamin K and the key role of lipids and
platelets when it comes to haemostasis.
One can no longer imagine treating hyperten-
sion without measuring blood pressure or in-
vestigating arrhythmia without the electrocar-
diogram. As a matter of course we require
tests that make sure that blood is pumped
round at the right pressure and in the right
rhythm. Still we hardly realise that we do not
dispose of a simple test to probe the system
that makes that there is any liquid at all to be
pumped round: the blood coagulation system.
Yet, coronary infarction, stroke, pulmonary
embolism and at least half a dozen of less
common but equally dangerous and disabling
diseases are simply caused by the fact that
blood stops to be liquid, so that no further flow
is possible, with disastrous consequences for
the tissues downstream; in other word: throm-
bosis. Thrombosis is at the basis of more than
half of all mortality in the western world and
still it remains somewhat of a stepchild in
circulation research. Until recently it was
hardly recognised that it is the main patho-
genic mechanism behind acute cardiovascular
disease. Haemostasis and blood coagulation
were considered to an area remote to the inter-
est of the cardiologist and almost incompre-
hensible anyhow.
Decreasing the coagulability of the
blood, i.e. the administration of anticoagulant
drugs, can substantially decrease the inci-
dence of thrombosis. It carries the risk of
bleeding and therefore should be carefully
controlled. One of the most serious handicaps
in the fight against thrombosis is that we do
not know who is going to get thrombosis and
therefore should receive anticoagulation.
Another problem is that the control of anti-
coagulation is a complicated and specialistic
affair. If one and the same test could first be
used for detection of a thrombotic tendency
and then show how this tendency decreases
upon anticoagulation, then a major step for-
ward would have been made. In other words,
we need a test, that, like blood pressure in hy-
pertension is a direct measure of the relevant
parameter and directly reflects the result of
pharmacological intervention. This article re-
polts on the results ofour quest for such a test.
At the moment we are in the exciting stage
where, on good grounds, we think that we
have found one, but the conclusive proof can
only be given by thorough and extensive clini-
cal testing, which is still lacking.
To present our results, it is not necessary
to discuss the haemostatic mechanism in
detail. The important thing to know is that
blood, upon contact with anything else than
the normal endothelial lining of the blood ves-
sel will start to generate thrombin via a com-
plicated interplay of plasmatic proteins, blood
platelets and the triggering components from
perivascular tissue. Thrombin is the active
agent that brings about haemostasis as well as
thrombosis. It also engages in a set of positive
and negative feedback reactions that ensure its
explosive generation at -, and limitation to -,
the site of vascular injury. Its enzymatic action
on plasma (coagulation), blood platelets
(aggregation and activation of procoagulant
activities) and on the cells of the vessel wall
(smooth muscle cells, fibroblasts endothelial
cells) that work together to achieve ar:rest of
The Endogenous Thrombin Potential 105
blood-flow locally. If a wound triggers this
process, the mechanism serves the vital func-
tion of haemostasis, i.e. the prevention of
blood loss. It is however also possible that
degenerative (atherosclerotic) changes in the
vessel wall are the trigger of this process, in
that case thrombosis ensues. This does not
necessarily lead to an immediate dramatic re-
sult, as long as it does not completely occlude
an important vessel. Given the fact however
than non-occlusive thrombosis is an important
step in the progression of atherosclerotic dis-
ease, it always is a step in the direction of a
possible dramatic ending.
Recent research, among others from the
group of Fuster, leaves little doubt that throm-
bus formation on a (ruptured) atherosclerotic
plaque is the main cause of coronary infarc-
tion. There is no reason to assume that in other
organs (e.g. brain) this would be different. All
in all it is evident that the capacity ofblood to
form thrombin is the key pathophysiological
function that we need to modulate in order to
prevent and treat thrombosis and that, there-
fore, we should be able to measure. The idea to
measure the thrombin that is generated in clot-
ting blood is older than the centuy but until
now the experimental procedures were ex-
tremely cumbersome and there was no accu-
rate and simple test that could be used in clini-
cal practice.
If a sample of blood is taken and some
tissue extract is added to mimic contact with
extravascular tissue, then thrombin is
generated, the concentration of which can be
Professor Dr med H. Coenraad Hemker
determined in subsamples taken from the mix-
ture. The life-time of thrombin is limited be-
cause plasma not only contains a (quick)
thrombin generating mechanism but also a
(slower) thrombin inhibiting system. This ex-
plains why the concentration of thrombin first
Fig 1 Thrombin Generation
Curves
Blood is brought o clot outside
the body by adding tissue factor
and calcium ions. Every half
minute the concentration of
thrombin is measured in a sub-
sample. Clotting occurs when a
thrombin level  of  10 nM is
reached (horizontal dotted l ine),
i e. early in the process. The nor-
mal curve rises to over 150 nM
In anticoagulation the peak
value is considerably ower. He-
parin Induced anticoagulation(H) is not accompanied by a sig-
nificant increase of the clotting
time, in contrast to oral anti-
coagulation (O)
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rises (as long as the rate of formation is higher
than the rate of breakdown) and then falls (as
soon as breakdown gains over generation), to
reach a zero level eventually (fig.l). The ac-
tual clotting of the blood occurs as soon as
5- 10nM of thrombin are formed but throm-
bin generation continues until a peak of about
200 nM is reached. This means that the bulk of
thrombin is generated after clotting has taken
place. This is the main reason that the clotting
time does not necessarily reflect the amount of
thrombin that will form. The haemostatic and
thrombotic action of thrombin is a con-
sequence of its enzymatic action on various
physiological substrates (fibrinogen, cell re-
ceptors etc.). The extent ofthis action is deter-
mined by the amount of thrombin and by the
time that it can act, i.e. to the area under the
thrombin - time curve (fig.1). This area, that
we called it the Endogenous Thrombin Poten-
tial (ETP), therefore is an essential parameter
in coagulation pathophysiology.
The clinical importance of the ETP be-
comes immediately evident if one considers
the two forrns of current anticoagulant medi-
cation: vitamin K antagonists and heparin.
The administration of vitamin K antagonists
decreases the concentration of thrombin-
forming proteins in the blood plasma; con-
sequently less thrombin can generate and the
ETP diminishes. In constrast, heparin (at clini-
cally applied doses) leaves the thrombin
generation system essentially unaffected but
diminishes the area under the thrombin - time
curue by accelerating thrombin breakdown.
Although their mode of action is completely
different and the only thing they have in com-
mon is that they both diminish the ETR both
treatments are effective in preventing throm-
bosis.
Since 1985 and, it may be mentioned
here, considerably helped by the Jung price
and other support from the Jung Stiftung, we
have directed our research towards the study
of thrombin generation and the ways in which
it can be influenced. This has led to a better un-
derstanding of the mode of action of heparins
and to the insight that not only anticoagulant
drugs, but also drugs that interfere with plate-
let function (aspirin, GPIIB-IIIA inhibitors
and others) owe at least part of their action to
inhibition of thrombin generation, as a con-
sequence of their inhibiting the procoagulant
function of platelets. In fact not a single an-
tithrombotic that we tested would not inhlbit
thrombin generation in blood! Moreover it ap-
peared that the ETP is increased in prothrom-
botic conditiions, such as the use of oral con-
traceptives and congenital deficiencies of an-
tithrombin and proteins C or S. So it seems
that the ETP rises in prothrombotic states and
lowers upon antithrombotic medication. Clot-
ting assays do not indicate prothrombotic
states and may or may not vary with an-
tithrombotic medication, depending on the
type of test and the type of drug used. The
bleeding time, apart from being impossible to
standardise, only prolongs with certain anti-
platelet drugs (aspirin) and is not shortened in
patients with a thrombotic tendency. It thus
appeared that the ETP would be a valuable
asset for the routine clinical laboratory.
Our early observations on the ETP were
done with the subsampling technique which
requires taking 20-40 samples in the course
of 15 minutes and determination of the throm-
bin concentration therein. This test is unsuit-
able for clinical and epidemiological research,
given the hundreds of determinations that may
be required per day. We therefore set out to
find a more practical method.
In principle, the solution is exceedingly
simple. One only needs to add a suitable
thrombin substrate to a blood samole and to
measure the amount of product formed during
the coagulation process. The ideal substrate
should be converted by thrombin only; should
render an easily detectable product; and
should not be depleted during coagulation. In
fact the concentration of substrate should be
so high that only variations of the concentra-
tion of thrombin determine the amount of
product formed, which amount by definition is
proportional to the ETP, i.e. to the amount of
any other substrate that thrombin generated in
the blood can converl.
P-nitroanilide-oligopeptides that are
specific thrombin-substrates have been
known since a long time. As a product they
render the yellowp-nitroaniline, which can be
measured spectrophotometrically. Their use
therefore imposes that the system must be, and
remain, optically clear. This precludes the use
of whole blood. Plasma must be pre-treated so
as to remove the fibrinogen, which upon
coagulation would render the sample turbid.
This can be done with a snake venom protease
that precipitates fibrinogen but leaves the
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thrombin generating- and inhibiting system
intact.
The existing chromogenic substrates for
thrombin are unsuitable for our purposes, be-
cause they are split too quickly and exhaust
during the coagulation process. We therefore
screened 
.a large number of different p-
nitroanilides, several dozens of which *" syn-
thesised ourselves. We did find a few suitable
ones. When such a substrate is added to
plasma and the optical density is monitored
then a curve such as in fig.2 should be ob-
tained. At any moment the-velocity of colour
formation is proportional to the concentration
of thrombin. The first derivative of the curve
therefore gives the course ofthrombin genera-
tion (as in fig. | ) and rhe amount ol Jroduct
formed in the end is proportional to the ETp(fig.2).
Mind however that we said .,should be
observed". In practice a complication arises
from the fact that thrombin partakes in a side-
reaction. With the plasma protein O,2-rracro-
globulin it forms a complex that has no activ-
ity with tlarge) physioiogical thrombin sub-
product formed by the o,2-macroglobulin-
thrombin complex. Because the vel,ocity of
complex Formation in itself is proportional
with the concentration of thrombin, ihe latter
part of the curve is proportional to the integral
of the former. We will not go into this into
more detail here. Suffice it to say that it is
possible, with the aid of a relatively simple
numeric calculation procedure (that can be
mogenic substrate that is not converted by a2-
macroglobulin-thrombin, but up to this mo-
ment we did not find one.
Does this end-level indeed always repre-
sent the real ETP? There is at least one caviat:
the thrombin generating process involves
several enzymes that resemble thrombin
closely. They may therefore possibly interact
with the signalling substrate that is added. Due
to their low concentrations this will not cause
a significant increase of product formation but
the substrate might inhibit thrombin formation
by competition with the natural processes.
Such inhibiting substrates were discarded as
not suitable. Competition is inevitable,
however, between the added substrate and the
natural thrombin inhibitors of plasma, because
inhibitors can only attack thrombin that is not
bound to the substrate. As we know the bind-
ing constant (Michaelis constant, Km) of the
enzyme-substrate interaction, we can calcu-
late what proportion of thrombin is bound at a
given substrate concentration (S/(Km+S)).
Inded it could be verified that the normal
thrombin decay processes were decreased in
that proportion, so that correction by a factor(Km+S)/S gives the required value.
Fig. 2 Conversion of a signal
substrate by thrombin gener-
a ted  in  c lo t t ing  p lasma
A chromogenic substrate is
added to  c lo t t ing  p lasma in  h igh
enough concentrat ion for the re-
action velocity to be proport ional
to  the  th rombin  concent ra t ion .
Product formation is monitored
via the optical density (sol id
l ine). The f irst derivative of this
curve (dotted l ine) then is pro-
por t iona l  to  the  th rombin  gen-
eratron curve (cf f ig. 1) The end-
level of product is proport ional
to  the  endogenous th rombin
potential
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Fig. 3 The E. T. P determina-
tion in practice.
In practice a complex forms be-
tween a part of the free throm-
bin that is generated and alPha-2
macroglobul in .  This  complex
has an enzymattc actlvlty
towards the chromogentc sub-
strate The optical density signal
that is obtained (l ine E) therefore
is not that which would be
theoretically expected (cf . f ig. 2)
By a mathematical procedure
curve E can be split into the Part
due to free thrombin (T, i. e the
curve as in fig. 2) and the Part
due to the complex (C, ProPor-
tional to the integral of T). The
end level of T gives the E T. P
pharmaca are used for this purpose: oral ad-
ministration of vitamin K antagonists or injec-
tion of heparin. Oral anticoagulant is present
at monitored by the prothrombin time. Since
the different types of this test have been made
comparable by the introduction of the inter-
national normalised ration (INR) this works
reasonably well in practice. The prothrombin
time is insensitive to heparin however. For this
drug the activated partial thromboplastin time
(APTT) is used. This test is very method-de-
pendent, almost impossible to standardise and
relatively insensitive; even less sensitive to
low molecular weight heparins than to unfrac-
tionated (classical) heparin. It therefore does
not surprise that in several studies no correla-
tions are found between the outcome of the
APTT and rethrombosis or bleeding in
patients that receive heparin. We must con-
clude that there is no adequate method for the
control of heparin treatment. Patients that are
treated for thrombosis usually first receive he-
parin, which acts immediately and then are
switched to oral anticoagulation. In the trans-
ition period there is no test that adequately in-
dicates the degree of anticoagulation.
Preliminary studies show that the ETP is
lowered by oral anticoagulation as well as by
heparin administration. It also indicates the
combined effect of mixed treatment. It seems
that an ETP of between 10 and 2O7o indicates
adequate anticoagulation. There is a mod-
erately good correlation between the ETP and
1 5
If the last two paragraphs may appear
slightly technical, we still think that they are
necessary, were it only to indicate that we can
account for the disturbances that we bring
about by probing the system.
The ETP-determination now being avail-
able we may well ask what the existing evi-
dence is that it can be used to screen for throm-
bosis prone states and to monitor the effect of
antithrombotic drugs.
The suggestive evidence that a high ETP
indicates a thrombotic risk is the following:
o The ETP is increased in women using oral
contraceptives
o The ETP is increased in congenital defi-
ciencies of the anticoagulant proteins C
and S as well as antithrombin.
o The ETP in platelet poor plasma is in-
creased in a subset of patients that got a
stroke at young age, in another subset it is
increased in platelet rich plasma.
o The ETP is increased in patients that are
admitted to hospital with active venous
thrombosis or coronary artery disease.
Decisive evidence that an increase of the ETP
indicates an increased thrombosis risk in the
population at large will have to come from
larger epidemiological studies.
We also have good reasons to surmise
that the ETP can be used as a universal param-
eter for the control of thrombosis treatment
and prevention. As stated above, two types of
i
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t the outcome of PT and APTT tests(f =0.6-0.7). The interesting question is
whether the ETP or the classical test is the bet-
ter indicator of bleeding or rethrombosis. This
question can only be solved by larger clinical
fials.
In conclusion, we may say that we have
developed a test that, if it keeps its promises,
may profoundly change the prevention and
treatment of thromboembolic disease. The
proof of the pudding will, as always, remain in
the eating.
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